Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells

Cécile Schiffer Mannioui,Laëtitia Lemaire,Laurent Poirot,Agnes Gouble,Sylvain Arnould,Andrew Scharenberg,Roman Galetto,Julianne Smith

doi:10.1186/2051-1426-1-s1-p34

Cécile Schiffer Mannioui, Laëtitia Lemaire + Show 6 more

Open Access

https://doi.org/10.1186/2051-1426-1-s1-p34

Copy DOI

Abstract

Meeting abstracts Encouraging data have emerged from adoptive T-cell therapies in advanced forms of cancer. Anti-tumor immunity is found in tumor infiltrating lymphocytes as well as engineered T cells where exogenous expression of a chimeric antigen receptor (CAR) confers cancer recognition on the

Highlights

Encouraging data have emerged from adoptive T-cell therapies in advanced forms of cancer
Anti-tumor immunity is found in tumor infiltrating lymphocytes as well as engineered T cells where exogenous expression of a chimeric antigen receptor (CAR) confers cancer recognition on the cells
Present adoptive immunotherapy methods are restricted to the use of autologous patient T-cells due to the limited persistence of allogeneic T cells and the potential for graft versus host disease (GvHD)

Summary

Introduction

Encouraging data have emerged from adoptive T-cell therapies in advanced forms of cancer. Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells Cécile Schiffer Mannioui*, Laëtitia Lemaire, Laurent Poirot, Agnes Gouble, Sylvain Arnould, Roman Galetto, Julianne Smith, Andrew Scharenberg

Results

Conclusion